Upon early-phase rituximab treatment, Bcl-2 family proteins are downregulated in leukemia cell lines due to preferential killing of CD20 + cells, causing decreased IL-10 production, inhibited STAT3 activation, and reduced interaction with the Bcl-2 promoter [50]. This evidence concerns the gene BCL2 and leukemia.